HydroxychloroquineStevens-Johnson syndrome following an off-label treatment: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1818卷 / 1期

关键词：

D O I：

10.1007/s40278-020-82415-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：135 / 135

相关论文

共 50 条

[31] LevomepromazineStevens-Johnson syndrome following off-label use: 2 case reports
Reactions Weekly, 2017, 1643 (1) : 183 - 183
[32] HydroxychloroquineOcular myasthenic syndrome following off-label use: case report
Reactions Weekly, 2020, 1823 (1) : 189 - 189
[33] BlinatumomabCytokine release syndrome following off-label use: case report
Reactions Weekly, 2021, 1867 (1) : 92 - 92
[34] Azithromycin/hydroxychloroquineDRESS syndrome following off-label use: case report
Reactions Weekly, 2020, 1819 (1) : 60 - 60
[35] Hyaluronic acidNicolau syndrome following off-label use: case report
Reactions Weekly, 2021, 1864 (1) : 177 - 177
[36] IvosidenibSweet's syndrome following an off-label use: case report
Reactions Weekly, 2022, 1910 (1) : 270 - 270
[37] QuetiapineNeuroleptic malignant syndrome following an off-label use: case report
Reactions Weekly, 2017, 1679 (1) : 172 - 172
[38] TocilizumabIntrauterine fetal demise following off-label treatment: case report
Reactions Weekly, 2022, 1899 (1) : 357 - 357
[39] RanibizumabRespiratory complication following off-label treatment with ranibizumab: case report
Reactions Weekly, 2018, 1717 (1) : 242 - 242
[40] Dabrafenib/trametinibNausea and vomiting following off-label treatment: case report
Reactions Weekly, 2020, 1830 (1) : 129 - 129

← 1 2 3 4 5 →